The RBP-Jκ Binding Sites within the RTA Promoter Regulate KSHV Latent Infection and Cell Proliferation

Jie Lu1, Subhash C. Verma2, Qiliang Cai1, Abhik Saha1, Richard Kuo Dzeng1, Erle S. Robertson1*

1 Department of Microbiology and Tumor Virology Program of the Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 2Department of Microbiology and Immunology, School of Medicine, University of Nevada, Reno, Nevada, United States of America

Abstract

Kaposi’s sarcoma-associated herpesvirus (KSHV) is tightly linked to at least two lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). However, the development of KSHV-mediated lymphoproliferative disease is not fully understood. Here, we generated two recombinant KSHV viruses deleted for the first RBP-Jκ binding site (RTA1st) and all three RBP-Jκ binding sites (RTAall) within the RTA promoter. Our results showed that RTA1st and RTAall recombinant viruses possess increased viral latency and a decreased capability for lytic replication in HEK 293 cells, enhancing colony formation and proliferation of infected cells. Furthermore, recombinant RTA1st and RTAall viruses showed greater infectivity in human peripheral blood mononuclear cells (PBMCs) relative to wt KSHV. Interestingly, KSHV BAC36 wt, RTA1st and RTAall recombinant viruses infected both T and B cells and all three viruses efficiently infected T and B cells in a time-dependent manner early after infection. Also, the capability of both RTA1st and RTAall recombinant viruses to infect CD19+ B cells was significantly enhanced. Surprisingly, RTA1st and RTAall recombinant viruses showed greater infectivity for CD3+ T cells up to 7 days. Furthermore, studies in Telomerase-immortalized human umbilical vein endothelial (TIVE) cells infected with KSHV corroborated our data that RTA1st and RTAall recombinant viruses have enhanced ability to persist in latently infected cells with increased proliferation. These recombinant viruses now provide a model to explore early stages of primary infection in human PBMCs and development of KSHV-associated lymphoproliferative diseases.

Introduction

Kaposi sarcoma-associated herpesvirus (KSHV, also known as human herpesvirus 8 [HHV8]) infection is pivotal to the development of Kaposi sarcoma (KS). KSHV is also strongly associated with two lymphoproliferative diseases, primary effusion lymphoma (PEL) and Multicentric Castleman’s disease (MCD) [1,2]. During its lifespan, KSHV undergoes latent and lytic cycle replication (reactivation). In comparison to lytic cycle replication, fewer genes are expressed in latent infection and a number of these genes are involved in disruption of the cell cycle, and in maintenance of the viral genome. One of those latent genes is Latency-associated nuclear antigen (LANA), encoded by KSHV open reading frame 73 (ORF73), which is critical for persistence of the viral episome and maintenance of latent infection in KSHV infected cells [3]. During lytic cycle replication, almost all viral genes are expressed in a staged temporal manner. The replication and transcription activator (RTA) is encoded by KSHV ORF50 and plays an essential role in the control of the lytic replication cycle. RTA can activate KSHV lytic genes including ORF6 (single-stranded DNA-binding, SSB), ORF21 (thymidine kinase, TS), ORF57 (mRNA transcript accumulation, MTA), ORF59 (polymerase processivity factor, PF-8), ORF 74 (vGPCR), K2 (vIL-6), K5 (MIR-2), K6 (vMIP-1), K8 (K-bZIP), K9 (vIRF), K12 (kaposin), K14(vOX-2) and polyadenylated nuclear (PAN) through direct binding with high affinity to RTA-responsive elements (RREs) or in combination with cellular transcription factors, RBP-Jκ, Ap-1, C/EBP-z, Oct-1, and Sp1 [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22]. Recombinant viruses that lack RTA establish latency quite efficiently but are unable to reactivate [23]. Our earlier studies also suggest that RTA contributes to the establishment of KSHV latency by activating LANA expression during the early stages of infection through the major effector of the Notch signaling pathway, recombination signal binding protein Jκ (RBP-Jκ). This mutual RTA/LANA feedback regulatory mechanism is likely to be a key event in establishment of KSHV latency and is yet to be completely elucidated.

RBP-Jκ, also named CBF1 or CSL, is a member of the CSL family (CBF1, Suppressor of Hairless, and Lag) and is the major downstream effector of the Notch signaling pathway [24,25]. RBP-Jκ functions on the target gene by recruiting distinct protein complexes to the promoter; RTA mimics Notch signaling and can activate target promoters by binding to the repression domain of RBP-Jκ, thereby activating promoters [17]. In KSHV-infected cells, RBP-Jκ mediates cooperative transactivation of KSHV genes, ORF57, K-bZIP, ORF60 (SSB), K14 (vGPCR), LANA, K8, ORF47 and RTA [12,15,17,26,27,28,29]. The KSHV RTA

Citation: Lu J, Verma SC, Cai Q, Saha A, Dzeng RK, et al. (2012) The RBP-Jκ Binding Sites within the RTA Promoter Regulate KSHV Latent Infection and Cell Proliferation. PLoS Pathog 8(1): e1002479. doi:10.1371/journal.ppat.1002479

Editor: Blossom Damania, University of North Carolina at Chapel Hill, United States of America

Received August 9, 2011; Accepted November 27, 2011; Published January 12, 2012

Copyright: © 2012 Lu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by public health service grants NCI CA091792, CA072510, and NIDCR DE017338 (to E.S.R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. E.S.R. is a scholar of the Leukemia and Lymphoma Society of America. S.C.V is supported by an NIH pathway to independence award (K99CA126182).

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: erle@mail.med.upenn.edu
Kaposi’s sarcoma-associated herpesvirus (KSHV) is tightly linked to at least two lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). The life cycle of KSHV consists of latent and lytic phase. RTA is the master switch for viral lytic replication. In this study, we first show that recombinant viruses deleted for the RBP-Jκ sites within the RTA promoter have a decreased capability for lytic replication, and thus enhanced colony formation and proliferation of infected cells. Interestingly, the recombinant viruses show greater infectivity in human peripheral blood mononuclear cells (PBMCs). The recombinant viruses also infected CD19+ B cells and CD3+ T cells with increased efficiency in a time-dependent manner and now provide a model which can be used to explore the early stages of primary infection in human PBMCs, as well as the development of KSHV-associated lymphoproliferative diseases.

Author Summary
Kaposi’s sarcoma-associated herpesvirus (KSHV) is tightly linked to at least two lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). The life cycle of KSHV consists of latent and lytic phase. RTA is the master switch for viral lytic replication. In this study, we first show that recombinant viruses deleted for the RBP-Jκ sites within the RTA promoter have a decreased capability for lytic replication, and thus enhanced colony formation and proliferation of infected cells. Interestingly, the recombinant viruses show greater infectivity in human peripheral blood mononuclear cells (PBMCs). The recombinant viruses also infected CD19+ B cells and CD3+ T cells with increased efficiency in a time-dependent manner and now provide a model which can be used to explore the early stages of primary infection in human PBMCs, as well as the development of KSHV-associated lymphoproliferative diseases.

Materials and Methods
Cells and plasmsids
Human embryonic kidney 293 (HEK 293) cells were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 5% bovine growth serum. De-identified Human peripheral blood mononuclear cells (PBMCs) were obtained from the University of Pennsylvania CFAR Immunology Core. The Core maintains an IRB approved protocol in which Declaration of Helsinki protocols were followed and each donor gave written, informed consent. Telomerase-immortalized human umbilical vein endothelial (TIVE) cells were a kind gift from Dr. Rolf Renne [44]. The wild-type KSHV BACmid, BAC36 wt, was provided by S. J. Gao (University of Texas, San Antonio, TX). Kanamycin (Kn) cassette containing plasmid, pL452 was obtained from the National Cancer Institute Biological Resources Branch.

Construction of KSHV mutants with in RTA promoter, BAC36-RTA1st and BAC36 RTAall within the RTA promoter
Mutagenesis of BAC36 was performed using the Red Recombination method as described previously [45]. The primers used were BAC 36-RTA1st, the forward PCR primer 5'- caaaaatgtttgtagaccaaccacctgtcgacgacgACATTCCGATGAT-CATATTACAATACCCTTAATT -3’ (target sequence is low-cased), and the reverse primer, 5'- tgtggagatcttttagagctagcttgctctgaAGAATCTAGTGTGATCCCCCCTCGAGGGACCTA -3' were used to amplify a Kan resistance cassette (underlined sequence is Kan cassette primer) flanked by BAC sequences (genomic position 69057 and 69171, NC_009333); BAC 36-RTAall, the forward PCR primer 5’- caaaaatgtttgtagaccaaccacctgtcgacgacgACATTCCGATGAT-CATATTACAATACCCTTAATT -3’ (target sequence is low-cased), and the reverse primer, 5'- tgtggagatcttttagagctagcttgctctgaAGAATCTAGTGTGATCCCCCCTCGAGGGACCTA -3’ were used to amplify a Kan resistance cassette (low-cased sequence is Kan cassette primer) flanked by BAC sequences (genomic position 69057 and 70417, NC_009333). The Kan cassette flanked with 50bp KSHV genomic sequence was electroporated into EL350 containing BAC36 at 1.75kV, and the resulting colonies plated on Kanamycin (50 μg/ml) and chloramphenicol (25 μg/ml) double selection plates followed by incubation at 30°C. BAC plasmid DNA was isolated from 10ml overnight cultures by the alkaline lysis procedure and characterized by restriction enzyme analysis followed by Southern blot analysis. The transformed single colonies were induced with 10% L (+) arabinose (Sigma-Aldrich, Inc., St. Louis, MO) for 1h, then plated to Chloramphenicol and Kanamycin selection plates, separately. The resulting single colonies on Chloramphenicol plates were inoculated in 10-ml of LB with chloramphenicol overnight at 30°C. Small-scale DNA isolation was performed to characterize the DNA of specific mutants, followed by Southern blot analysis. All the clones were confirmed by DNA sequencing using the University of Pennsylvania Perelman School of Medicine sequencing core. Large preparations of KSHV BAC plasmids were obtained from 500-ml E. coli cultures with the Qiagen Large
construct kit (Qiagen, Inc., Valencia, CA) according to manufacturer instructions.

Southern blot and junction PCR analysis

The DNA probe used for Southern blot hybridizations was amplified as a 1.4-kb fragment (corresponding to the RBP-Jk locus of RTA promoter) with the KSHV genome as the template and primer set forward: 5’-ATGCAACGGGTTAGCCTGCT-CAGGC-3’, and reverse, 5’-TGGCAAGAGGACAC-GAGGCTGTCG-3’. Purified KSHV BAC plasmid DNA was digested with XhoI and resolved on 0.65% agarose gels in 0.5X Tris-borate-EDTA buffer for 14 to 18 h at 40 V. DNA fragments were visualized by ethidium bromide staining, denatured, and transferred to Zeta- Probe GT Genomic testing blot membranes (Bio-Rad Inc, Hercules, CA). DNA probes were radioabeled with [γ-32P]dCTP with the NEBlot (New England Biolabs, Inc., Ipswich, MA). Prehybridization was performed at 63°C for 1 h in a hybridization buffer (7% sodium dodecyl sulfate, 10% polyethylene glycol, 1.5X SSPE (1X SSPE is 0.18 M NaCl, 10 mM NaPO4, and 1 mM EDTA, pH 7.7)). DNA blots were hybridized with radiolabeled probes in the same solution at 63°C for about 7 h. Blots were washed twice for 15 min with 2X SSC (1X SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and 0.1% sodium dodecyl sulfate and twice for 30 min with 0.1X SSC-0.1% sodium dodecyl sulfate at 63°C. Blots were exposed to a Phosphoimager plate (Molecular Dynamics, Inc. Sunnyvale, CA) overnight at room temperature followed by scanning with the Typhoon 9200 (GE Healthcare Inc., Piscataway, NJ).

Junction PCRs were performed to identify the expected deletions. The primers used were RTA-Fa (genomic position 69010 to 69291, NC_009333) 5’ TCCCAGCCAGTCTGAGTCGTCGT 3’ and 5’ GTCGCCACTGTCGCCAGTCGGC 3’; RTA-m (genomic position 69010 to 70537, NC_009333) 5’ TCCCGAGG- CATGTCCTGCTGTCGT 3’ and 5’ GCCGGGATACTGGCAGCATGCG 3’.

Reconstitution of recombinant viruses, virus induction and determination of virus copies

Purified Bac36 DNAs were transfected into 293 cells via CaPO4 method. Hygromycin B (150 μg/ml) was then added for selection 24 h after transfection. Three weeks after selection, homogenous populations of GFP-positive cells harboring KSHV Bac36 DNAs were obtained. Butyric Acid at a final concentration of 3 mM and TPA (Sigma) at 20 ng/ml was used for lytic induction. Cell suspensions were centrifuged at 3000 rpm for 20 min and the supernatant was filtered through a 0.45 μm cellulose acetate filter. The viral particles were concentrated by ultracentrifugation at 70,000xg at 4°C and stored at −90°C.

Infection of PBMCs and TIVE cells with recombinant KSHV virions

Infection of PBMCs was performed as described previously [43]. In brief, 1x107 were infected by incubation with virus suspension in 1ml of RPMI 1640 (10% FBS) medium in the presence of Polybrene at a final concentration 3 ng/ml (Sigma, Marborough, MA) and incubated for 4 h in 37°C. Cells were centrifuged for 5min at 1500rpm, the supernatant discarded, pelleted cells were washed by fresh RPMI medium for 2 times and resuspended in fresh RPMI 1640 (10% FBS) medium in 6-well plates and culture at 5% CO2, 37°C humidified incubator.

TIVE cells were cultured in 12-well plates to 60% confluence in Medium 199 supplemented with 20% FBS, 200 mM L-glutamine, 5 mg/ml Penicillin/Streptomycin/P/S and 10 mg/ml Endothelial cell growth supplement from bovine neural tissue. Concentrated viruses were added to the supernatant in the presence of Polybrene (4 μg/ml) and spun at 2,500 rpm for 1 h at room temperature. The supernatants were removed and washed twice and then incubated with fresh medium. GFP expression was used to monitor infection under fluorescence microscope (Olympus Inc., Melville, NY).

Extraction and determination of intracellular and extracellular viral DNAs

For quantitation of intracellular viral DNA, cells were harvested and washed twice with 1xPBS to remove the residual cells. Viruses were incubated by HMW buffer (10mM Tris-HCl pH 8.0, 150mM NaCl, 10mM EDTA, 0.5% SDS) for 2 hrs at 55°C. 0.5 mg/ml proteinase K was added and incubated at 37°C overnight with subsequent extraction in phenol/chloroform/isopropanol. Viral DNA was treated with RNase, then precipitated and resuspended in water. Extracellular viral DNA was extracted from culture supernatants as essentially described previously [35,43]. In brief, virions were pelleted down at 70,000xg for 2 hrs at 4°C and resuspended. Cellular DNAs and free viral DNAs were removed by treatment with DNase I at 37°C for 1–2 hrs. Virion DNA was treated with HMW buffer for 20 minutes. lysates were treated with proteinase K overnight at 37°C with subsequent extraction with phenol/chloroform/isopropanol. Intracellular and extracellular viral DNAs were quantitated by real-time DNA PCR for TR (5’ GGTCCTCCCCAAGCCTGCTCA 3’, and 5’ GGGGACCCCGGGGCCAGGAG 3’). GAPDH and BAC36 DNAs were the standards for intracellular and extracellular viral DNAs, respectively.

Quantitation of KSHV RNA

Total RNA from infected PBMCs were extracted by using TRIzol (Invitrogen, Inc., Carlsbad, CA) and 1 μg DNase-treated total RNA were used to generate cDNA using the High capacity RNA-to-cDNA kit (Applied Biosystems Inc., Foster City, CA) according to manufacturer’s instructions. RT-qPCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems Inc, Carlsbad, CA) or Opticon 2 Real-Time PCR System. The reactions were carried out in a 96-well plate at 95°C for 10 min, followed by 35 cycles at 95°C for 30 s, 51°C for 30 s and then 72°C for 40 s. The differences of cycle threshold values (CT) between the samples (ΔCT) were calculated after standardization by GAPDH and converted to fold changes using one of the samples as a standard (1-fold). The primers used were LANA: 5’ CATCAGGAATCT-CAGGTCTGTG 3’, 5’ GGTGGAAGAAGCCATAATCTC 3’; RTA: 5’ CAGACGGTGTCAGTCAAGGC 3’, 5’ ACATGA-CGTCCAGGAAAGAAGC 3’; GAPDH 5’ GTGCTCACATGCGA-ACTGT GA 3’, 5’ ACGACAGCTTTGTCAGCTC 3’. All the reactions were run in triplicates.

Immunostaining

Cells were applied to a slide well and fixed with 4% paraformaldehyde with 0.1% Triton X-100, and blocked with 10% BSA. Cells were then incubated with a primary antibody (Mouse anti-LANA), and specific signals were detected with a secondary antibody conjugated with Alexa Fluor 594 (Invitrogen, Carlsbad, CA). The cells were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Images were observed and recorded with a Fluoview FV300 microscope (Olympus Inc., Melville, NY).

Colony formation and growth assay

BAC36 wt, BAC RTA1st and BAC RTAall transfected 293 cells were selected for 3–4 weeks with Hygromycin B. 300 stably
transformed 293 cells were seeded in 6 cm Petri dish in DMEM supplemented with 10% FBS, Hygromycin B (150 ng/ml) and Difco Noble Agar (BD, Franklin Lakes, NJ) (0.5%). After 2 weeks of growth, the colony was monitored and photographed under fluorescence microscope (Olympus Inc., Melville, NY). The plates were scanned by Typhoon 9200 for GFP signals and the colony number was quantitated using the Odyssey V3.0 software.

Flow cytometry
BAC36 wt, BAC RTA1st and BAC RTAall stably transfected 293 cells were harvested and fixed in 1% paraformaldehyde for 30-60 min. The fixed cells were washed twice by 1XPBS and analyzed using on FACSCalibur based on GFP signals.

Infectected PBMCs cells were stained essentially as described previously [46,47]. Briefly, PBMCs were harvested and washed at 1dpi, 2dpi, 4dpi and 7dpi. T cells and B cells were detected by using the APC conjugated anti-CD3 and Perpcy 5.5 conjugated anti-CD19 mAbs (BD Biosciences, San Jose, CA). GFP signals were used to monitor KSHV positive cells. Data were acquired on FACS Calibur equipped with CellQuest Pro software and analyzed using FlowJo software.

Statistics
Data are shown as mean values with standard errors of the means (SEM). The significance of differences in the mean values was evaluated by 2-tailed Student’s t test. P<0.05 was considered statistically significant.

Results
Generation of recombinant KSHV viruses deleted for RBP-Jk binding sites within the RTA promoter (RTA1st and RTAall)
Our previous studies showed that RTA contributes to establishment of KSHV latency by activating LANA expression during the early stages of infection via RBP-Jk, the major effector of the Notch signaling pathway [28]. The activity of the RTA promoter was reduced about 40% in the truncations of first RBP-Jk and all three RBP-Jk binding site within RTA promoter compared to the wt promoter [30]. To investigate the roles of the RBP-Jk binding sites in the RTA promoter, we constructed two KSHV recombinant viruses, BAC RTA1st with a deletion of the first RBP-Jk binding site and RTAall with deletion of all three RBP-Jk binding sites. BAC36 wt carries the full KSHV genome, a GFP tag, and a eukaryotic resistance gene, hygromycin [48]. Infectious KSHV can be reconstituted by transfection of wt DNA into 293 cells [48]. Using the BAC36 wt as a template, we transfected BAC36 wt DNA into 293 cells [48]. Using the BAC36 wt as a template, we designed PCR primers so that the RBP-Jk binding sites in the RTA promoter were removed from the genome. Fig. 1A and B shows a schematic for the generation of the recombinant BAC RTA1st and RTAall using PCR primers that integrated the Kanamycin resistance gene (Neo: the neo cassette is resistant to Neomycin or Kanamycin in prokaryotes) and two loxP sites from plasmid pL52 into the BAC36 genome, replacing the RBP-Jk binding sites of the RTA promoter. LoxP is the substrate sequence of Cre recombinase, so the insert fragment between two loxP sites (including neo cassette) can be subsequently removed by expressing Cre recombinase after induction by L-arabinose [49]. A PCR product containing Neo flanked by loxP sites and two fragments of 50-bp KSHV sequences from the two ends of the RBP-Jk site in the RTA promoter was generated using pL52 plasmid as a template. This PCR product was transfected into BAC36 wt-E.coli 350 to remove the RBP-Jk site in the RTA promoter after homologous recombination and Cre-mediated excision of Neo’. The resulting BAC recombinants were screened and analyzed on 0.65% agarose and subsequently by southern blot analysis to show that the RBP-Jk binding site in the RTA promoter was removed from the KSHV genome (Fig. 1A and C).

Digestion of the BAC36 wt DNA with Xhol generated one 12584kb fragment at the RBP-Jk binding site in the RTA promoter. For BAC RTA1st, replacement of the RBP-Jk binding site with the Kan cassette changes the two fragment sizes to 9486bp and 4973bp. After induction, the fragment between two loxP sites was removed, so the smaller fragment (4973bp) shifted in size to 3176kb, indicating removal of Kan cassette. Southern blot showed the presence of a 3kb band before induction and a unique 3kb band in recombinant BAC RTA1st when hybridized with a probe within the RBP-Jk binding site (Fig. 1A and C). To further confirm whether the altered digestion pattern of the BAC mutants was the result of the expected recombination, we carried out junction PCR by using the primers designed at the recombination site showing that the junction bands in the BAC RTA1st shifted based on the presence of the remaining loxP site and Xhol site (Fig. 1D). Similarly, For BAC RTAall replacement of the RBP-Jk binding sites with the Kanamycin cassette changes the two fragment sizes to 8240bp and 4973bp. After induction, the fragment between two loxP sites was removed, so the smaller fragment (4972bp) shifted in size to 3176kb - indicating removal of the Kan cassette. Southern blot showed the presence of a 3kb band before induction and a unique 3kb band in the recombinant BAC RTAall when hybridized with a probe within the RBP-Jk binding site (Fig. 1B and E). Junction PCR showed that the junction bands in the BAC RTAall shifted based on the presence of the remaining loxP site and Xhol site (Fig. 1F). Finally, the PCR products were sequenced to confirm the expected mutation.

BAC RTA1st and RTAall recombinant KSHV stable 293 cells had a decreased capability for lytic replication
To reconstitute recombinant viruses, we transfected BAC36 wt, RTA1st and RTAall DNAs into 293 cells. The transfection efficiencies were monitored by the fluorescence microscopy. GFP positive cells were detected after 24–48h post-transfection (data not shown). Positive cells were enriched by hygromycin selection, generating 293 cell lines bearing BAC36 wt, RTA1st and RTAall (Fig. 2A). Subsequently, the cells were fixed and immunostained against LANA to confirm that BAC 36 wt and RTA1st and RTAall (Fig. 2A). Subsequently, the cells were fixed and immunostained against LANA to confirm that BAC 36 wt and RTA1st and RTAall stable cell lines harbored the KSHV genome (Fig. 2B). Similar levels of GFP positive signals and LANA staining were observed for all three stably transfected cell lines generated due to hygromycin selection.

To ensure that both RTA1st and RTAall stable cells were able to produce recombinant viruses after lytic reactivation, the cells were treated with TPA and butyric acid to induce lytic reactivation. Whole cell lysates were prepared from the uninduced and induced cells at 24, 48, 72 hours post induction (hpi), and the expression of LANA and RTA were analyzed by western blot analysis using the corresponding specific antibodies. The results showed that LANA expression exhibits a slight decrease after induction in BAC36 wt-293 cells at 48 and 72 hpi as more cells switch to lytic replication. However, there was no obvious difference in RTA1st and RTAall-293 cells (Fig. 3A). This may be due to the fact that more cells were infected with RBP-Jk mutant viruses in latent phase with higher levels of LANA. In the wild type, RTA expression was not affected thus most of the viral genome copies underwent lytic reactivation thereby expression of latent protein, LANA diminished over time. This is further evident by the levels of RTA, which increased, in a time dependent manner after induction with TPA and butyric acid, in wt BAC36-293 cells (Fig. 3A). Notably, though RTA
Figure 1. Generation of two recombinant KSHV BACmids with deletion of RBP-Jk sites in the RTA promoter. (A) Schematic diagram showing generation of BAC RTA1st, a recombinant BAC36 with first RBP-Jk site deletion in the RTA promoter. (B) Schematic diagram showing generation of BAC RTA36, a recombinant BAC 36 with deletion of first, 2nd and 3rd RBP-Jk site in the RTA promoter. (C) Ethidium bromide-stained gel and southern blots with BAC36 wt (lane 1) and the mutated BACmid, RTA1st (Unfloxed, lane 2) and RTA1st (floxed, lane 3), cleaved with XhoI. (D) PCR analysis for Bac36 wt and RTA1st recombinant virus at the junction of deletion of RBP-Jk site within RTA promoter. (E) Ethidium bromide-stained gel of RTA1st recombinant virus.
expression was increased in a time-dependent manner after induction in all cell lines, the levels of RTA expression was reduced in RTA1st and RTAall-293 was much lower than seen in BAC36 wt-293 cells. This suggests that RTA expression was reduced in RTA1st and RTAall-293 cells (Fig. 3A). In addition, the viruses were collected from supernatant of the induced BAC36 wt, RTA1st and RTAall-293 cells and quantitated for virion particles by quantitative PCR analysis. The results showed that RTA1st and RTAall-293 cells produced fewer KSHV genomes, suggesting a decrease in virion production post-induction (Fig. 3B). This confirms our hypothesis that deletion of the RBP-Jk binding sites in the RTA promoter of KSHV results in an attenuated lytic cycle and thus decreased viral progeny. Furthermore, total DNA was extracted from BAC36 wt, RTA1st and RTAall-293 cells. Intracellular viral DNA levels were determined by quantitative PCR analysis standardized by GAPDH. The result showed that RTA1st and RTAall-293 cells had a greater number of viral copies compared to BAC36 wt-293 cells, further indicating that RTA1st and RTAall deficient viruses exhibited a decrease in lytic capability although the genome copy numbers were greater (Fig. 3C).

**RTA1st and RTAall recombinant KSHV showed enhanced latency and promoted cell growth and proliferation of 293 cells**

BAC36 wt, RTA1st and RTAall are recombinant KSHV viruses harboring a GFP marker which allows us to track viral genome stability in 293 cells. Furthermore, RTA1st and RTAall 293 cells possessed higher intracellular viral DNA copies than BAC36 wt-293 cells. We postulated that both of them should have increased GFP signals. Flow cytometry was performed based on GFP signals for BAC36 wt, RTA1st and RTAall-293 cells. Interestingly, RTA1st and RTAall-293 cells showed approximately 78% and 93% GFP fluorescence intensity, respectively. However, only 41% GFP fluorescence intensity was seen for BAC36 wt-293 cells (Fig 4A, B) and pellets from collected RTA1st and RTAall-293 cells also had a more intense green color based on visual inspection when compared to BAC36 wt-293 cells (data not shown).

KSHV is a known human oncovirus and is associated with cellular transformation [31,50,51]. Therefore we wanted to determine the proliferation rate for BAC36 wt, RTA1st and RTAall-293 cells. Cells were starved in DMEM with 0.1% FBS overnight. Next day, media were replaced with DMEM supplemented with 5% FBS. Cells were cultured for 24 hrs and harvested for analysis by flow cytometer. Interestingly, RTA1st and RTAall-293 cells had a higher percentage of cells (55.7% and 59.4%) comparing to BAC36 wt-293 (51.8%) in G1 phase which was consistent after multiple repeats (Fig. 4C). These results suggested that RTA1st and RTAall recombinant viruses can promote cell growth and proliferation in the infected cells. In addition, cells harboring more viral genome copies should have an enhanced capability for driving cell growth. Therefore we tested this hypothesis with a colony formation assay. The colonies were photographed using fluorescence microscopy and scanned by a Typhoon 9200 system based on GFP signals. Surprisingly, the average size of hygromycin-resistant colonies for RTA1st and RTAall-293 cells was distinctively bigger (almost double) relative to BAC36 wt-293 cells (Fig. 4D), indicating that RTA1st and RTAall recombinant viruses possess enhanced capability for cell growth. Furthermore, GFP positive colonies were scanned and quantitat-
Figure 2. Transfection of 293 cells with BAC36 wt, BAC RTA1st and BAC RTAall DNAs. (A) Cells were transfected with BAC36 wt, BAC RTA1st and BAC RTAall DNAs. GFP expression levels were monitored by fluorescent microscopy 2 days after transfection, and the transfected cells were split and selected with Hygromycin B. The hygromycin-resistant cells were pooled and passed three to four times. The homogenous population of GFP-positive cells harboring KSHV wild-type and mutant genomes were obtained. (B) Immunofluorescence analysis for LANA in BAC36-293 BAC RTA1st-293 and BAC RTAall-293 cells.
doi:10.1371/journal.ppat.1002479.g002
Immunofluorescence assays showed that LANA signals were detected in BAC36 wt, RTA1st and RTAall infected PBMCs at 1 dpi, 2 dpi, 4 dpi and 7 dpi indicating a successful infection (Fig. 6A). DNase treated total RNA from infected PBMCs at 1 dpi, 2 dpi, 4 dpi and 7 dpi were used to generate cDNA and signals of RTA and LANA transcripts quantitated by real-time PCR. The results showed that LANA expression from BAC36 wt infected PBMCs increased in a time-dependent manner. Furthermore, RTA1st and RTAall recombinant viruses infected PBMCs showed higher LANA mRNA expression from 1 dpi to 7 dpi, indicating that deletion of the RBP-Jκ cognate sequences within the RTA promoter can result in greater stringency for latent infection (Fig. 6B). Additionally, mRNA of RTA was also analyzed and showed a peak at 2 dpi in BAC36 wt and recombinant viruses (Fig. 6C), perhaps promoting lytic infection at an early stage [47]. However, compared to BAC36 wt, RT-PCR results from RTA mRNA showed lower levels in RTA1st and RTAall infected PBMCs from 1 dpi to 7 dpi with almost no significant change with RTAall recombinant virus (Fig. 6C). This suggests that deletion of the RBP-Jκ cognate sequences in the promoter led to a dramatic loss in the ability of the recombinant viruses to induce lytic cycle activation, and as a result more tightly maintain latent infection (Fig 6C). Furthermore, KSHV ORF6 which encodes the single-stranded DNA (ssDNA) binding protein and is tightly associated with DNA replication, showed increased expression in RTA1st and RTAall infected PBMCs compared to BAC36 wt infected PBMCs (Fig 7A). This suggests that KSHV replication is actively engaged although latent infection is more stringent (Fig 7A). ORF49 encoded by KSHV lies adjacent to and is transcribed in the opposite orientation to RTA. It also co-operates with RTA to activate KSHV lytic cycle [53]. We also monitored the activity of ORF49, which cooperates with RTA during lytic replication through activation of several lytic promoters containing AP-1 sites [53]. The mRNA level was initially higher for recombinants at 1 dpi (Fig 7B). However, at 4 dpi and 7 dpi, the ORF49 transcript levels for the recombinants were much lower than BAC36 wt with RTAall greater than 2-fold less at 4 dpi. By 7 dpi, both RTA1st and RTAall were further depressed compared to BAC36 wt to about 3-fold (Fig. 7B). This suggests that active lytic replication of KSHV was dramatically reduced by 7 dpi with a greater propensity for...
maintaining latency. We then investigated changes in the K8 and K9 transcript levels. The early lytic protein K8 [54] showed a general increase in transcript levels over the 7 day period. However, the levels of K8 transcripts for RTA1st and RTAall were generally lower than that of the BAC36 wt virus (Fig 7C). Interestingly, ORF K9 which encodes for vIRF, a homolog to members of the interferon (IFN) regulatory factor (IRF) and important for regulating intracellular interferon signal transduction [55], increased dramatically by 2 days, with BAC36 wt continuing to increase in K9 transcript levels. At 7 days all viruses showed a drastic reduction in K9 transcript levels (Fig 7D). These results suggest a level of regulation of these transcripts which is important for controlling latent infection in KSHV.

RTA1st and RTAall recombinant viruses showed enhanced ability to infect T and B cells during primary infection

Human PBMCs contains lymphoid cells consisting of both T and B cells. The results above showed that RTA1st and RTAall recombinant viruses have an enhanced propensity for latent infection during the early stages of in vitro infection. Recently, Myoung and Ganem showed that 20–40% T and 4%–5% B cells from human tonsillar cultures can be infected [36]. However, only B cells support viral replication and produce progeny. Here, we are interested in the ability of KSHV to infect T and B cells from PBMCs during early infection. APC–conjugated anti-CD3 and PerCpCy 5.5-conjugated anti-CD19 mAbs were used to detect infected T and B cells, respectively. GFP signals were used to detect KSHV-positive cells. Our results showed that GFP positive T cells were detected as early as 1 dpi (Fig 8A). The GFP positive T cells infected by BAC36 wt virus was slightly changed relative to RTA1st and RTAall recombinant viruses. At 2 dpi, the proportion of GFP+ CD3+ T cells was 1.65%, 1.86% and 1.64%, respectively. The percentage of GFP+ CD3+ T cells infected by BAC36 wt, RTA1st and RTAall recombinant viruses were increased to 1.68%, 3.32% and 3.7% at 4 dpi, respectively. At 7 dpi, T cells were infected continuously in a time-dependent manner and the proportion of GFP+ CD3+ T cells were 3.98% and 4.48% for RTA1st and RTAall relative to 2.04% for BAC36 wt (Fig 8A). These results further confirms that T cells were infected and that mutation of RBPs/Jk sites within RTA promoter can result in an increase in T cell infection as determined by GFP signals.

We then investigated the response of B cells exposed to KSHV. At 1 dpi the percentage of GFP+ CD19+ B cells were 0.48% for BAC36 wt, 0.72% for RTA1st and 0.79% RTAall recombinant viruses (Fig 8B). The next day, the proportion of GFP+ CD19+ B cells increased to 1.77% for BAC36 wt, 1.75% for RTA1st and 1.74% RTAall. At 4 dpi, the percentage of GFP+ CD19+ B cells further increased to 2.03% for BAC36 wt, 2.49% for RTA1st and 2.51% RTAall. At 7 dpi, the GFP+ CD19+ B cells was similar to that at 4dpi suggesting that little or no further increase in B cell infection was seen. Furthermore, RTA1st and RTAall recombinant viruses infected B cells (2.13% and 2.47%) show a consistently higher rate of infection compared to BAC36 wt infected B cells (2.05%) (Fig 8B). This suggests that PBMCs were continually infected over the 7day period. Interestingly, GFP+ CD3+ T cells had a higher rate of infection compared to GFP+ CD19+ B cells from the BAC36 wt infected PBMCs (Fig 8C). Importantly, RTA1st and RTAall recombinant viruses possessed a higher infectivity compared to BAC36 wt virus for both infected T and B cells (Fig 8D). The overall amount of the GFP positive cells showed a definite increase in a time-dependent manner (Fig 8E). This further supports our previous data showing increased fluorescent signal from 2dpi to 7dpi. In general when compared to BAC36 wt, RTA1st and RTAall recombinant viruses infected PBMCs showed more GFP-positive cells, suggesting an increased ability for infection and maintenance of the KSHV genome within the first 7days after infection (Fig 8E).

RTA1st and RTAall recombinant viruses showed an increased capability for infection and proliferation in long-term-infected telomerase-immortalized endothelial cells

Typically, infected PBMCs stopped clumping and most cells begin to die after 7 dpi. In our experiments, no transformation and/or immortalization was observed in infected PBMCs in vitro during the 7-day period. Thus it was difficult to monitor the effect of long-term infection of RTA1st and RTAall recombinant viruses. Here, we used recently developed telomerase-immortalized endothelial cells (TIVE) to monitor the ability of RTA1st and RTAall recombinant viruses to infect TIVE cells [44]. TIVE cells were infected with BAC36 wt, RTA1st and RTAall recombinant viruses as indicated in the materials and methods. GFP signals confirmed latent infection by BAC36 wt, RTA1st and RTAall viruses and photographs were taken at 1 week post-infection (wpi), 2wpi and 4wpi (Fig 9A). We determined the copy number of KSHV genomes in infected TIVE as a measure of the persistence of the genomes. Total DNAs were extracted from BAC36 wt, RTA1st and RTAall recombinant viruses infected TIVE cells at 1, 2, 4wpi. Intracellular viral DNAs were determined by a quantitative PCR analysis standardized by GAPDH. The result showed that copy numbers of BAC36 wt, RTA1st and RTAall recombinant viruses were a slightly lower at 4wpi compared to 1 and 2wpi suggesting a possible loss of KSHV genome due to genome tethering instability. This phenomenon was also seen in BCBL-1-derived cell-free virus infected TIVE cells [44]. However, RTA1st and RTAall recombinant viruses maintained a similar copy number in the infected TIVE cells and infection levels were consistently greater than the BAC36 wt infected TIVE cells at 1 to 4wpi (Fig 9B). These results further indicated that RTA1st and RTAall recombinant viruses exhibited a decrease in lytic capability. Previous studies showed that KSHV long-term-infected telomerase-immortalized endothelial cells exhibit a significant increase in number of cells in the S phase [44]. Here, we cultured infected TIVE cells for 4 weeks, harvested, fixed and stained them with propidium iodide. Flow cytometry analysis showed that the RTA1st and RTAall infected TIVE cells had an increased S phase population (29.4% and 32.1%), relative to BAC36 wt (25%) at 1wpi. Therefore, the recombinant viruses infected cells showed an enhanced capability to proliferate (Fig 9C). Similar patterns were seen at 2wpi and 4wpi where RTA1st and RTAall all exhibited enhanced KSHV Latent Infection and Proliferation
increased S phase populations, further supporting our previous hypothesis that RTA\textsubscript{1st} and RTA\textsubscript{all} recombinant viruses can increase cell proliferation in TIVE cells.

**Discussion**

KSHV RTA is an immediate early protein (IE) that initiates KSHV lytic reactivation from latent infection. It can directly or indirectly stimulate the transcription of a cluster of lytic genes as a transcription factor through binding to specific promoter sequences. RTA is a key regulator for KSHV reactivation because its expression is sufficient to activate the entire lytic cycle. Therefore understanding the regulation of RTA is to provide a better clue related to KSHV infection and tumorigenicity. RTA-deficient viruses are able to establish latency but are unable to reactivate [23]. Here, in an effort to explore KSHV latency and reactivation we generated two recombinant viruses which possess different latency and reactivation profiles compared to BAC36 wt. They

---

Figure 5. Comparisons of relative infectivity for BAC36 wt, RTA\textsubscript{1st} and RTA\textsubscript{all} recombinant viruses. (A) PBMCs were infected by KSHV BAC36 wt, RTA\textsubscript{1st} and RTA\textsubscript{all} viruses with equally loading. GFP expression was monitored under a fluorescent microscope after 2dpi, 4dpi and 7dpi. (B) Intracellular KSHV viral genome copies were measured by a real-time PCR with primers to TR at 1 dpi, 2 dpi, 4 dpi and 7 dpi. (C) Extracellular KSHV progeny virion progenies were analyzed by a real-time PCR with primers to TR at 1 dpi, 2 dpi, 4 dpi and 7 dpi. Dpi, days post infection. \*P<0.05; \**P<0.01; \***P<0.001 by Student's t test.

doi:10.1371/journal.ppat.1002479.g005
serve as important reagents which allow us to examine the early-stages of KSHV infection. This provides a model with which to understand the development of KSHV-associated lymphoproliferative diseases.

RTA is an IE protein and its expression is also affected by other viral or cellular factors. For example, RTA up-regulates its own expression through interaction with the CCAAT/enhancer binding protein alpha (C/EBPα) at its promoter [20,56]. Furthermore, RTA can down-regulate its ability for activating specific viral promoters by cooperating with the viral protein b-Zip, an early protein encoded by ORF K8 [57,58]. Our previous studies showed that loss of one of those sites can potentially affect the
overall regulation of all four RBP-Jk sites within the RTA promoter [30]. Importantly, the observation that RTA\textsubscript{1st} and RTA\textsubscript{all} recombinant viruses enhance latency and can promote cell growth in 293 cells caused us to further investigate these mutations during early infection.

Many human cancers are associated with tumor viruses [59] and many are detected in PBMCs. Human papillomavirus (HPV) DNA has been found as an episomal form in PBMCs, but no transcripts are detected [60,61]. Recent studies showed that PBMCs of haematuric cattle are additional reservoir of bovine papillomavirus type 2 [62]. Though Hepatitis C virus (HCV) is detected in PBMCs of infected individuals, infected PBMCs are not observed in co-culture with cell culture systems producing HCV virions. This implicates additional reservoirs for the virus and allows for PBMCs infection [63]. However, Polyomavirus BK (BKV), one of the tumor viruses associated with nephropathy in renal allografts, elicits a BKV-specific proliferative response in the PBMCs of healthy individuals and bone marrow transplant recipients [64,65]. Another human tumor virus, John Cunningham virus (JCV) is detectable in the PBMCs of immunoimpaired and healthy individuals [66]. The well studied EBV infects B lymphocytes and induces their differentiation, proliferation [32]. Furthermore, PBMCs infected EBV lead to immortalization and transformation of B cells [47]. However, the mechanism by which KSHV infects and transforms B cells is not fully understood. Thus, the development of lymphoproliferative diseases which include primary effusion lymphoma and multicentric Castleman’s disease is yet to be fully understood. Recently, PBMCs from marmosets orally and intravenously infected with rKSHV.219, showed the presence of the viral genome and LANA expression [42]. Additionally, T and B cells isolated from primary human tonsillar cells were shown to be infected by KSHV virions, although more T cells were infected. However, these infections were abortive without further lytic infection [35,36]. Other T cells types from human PBMCs can support KSHV infection [67,68,69]. Similar patterns were observed showing that both T and B cells from human PBMCs are effectively infected up to 7 days, suggesting that KSHV has a different mode of infection compared EBV infection. Obviously, many more T cells were infected in a time-dependent manner, perhaps due to the large population of T cells or a receptor on T cells not highly expressed in B cells. At 4 and 7 dpi, T cells were infected up to 4.48%, over 2 times the percentage of B cells infected. This phenomenon was also seen in KSHV infected tonsillar cells, though the life span of infected cells was
Figure 8. FACS analysis of T cells, B cells and GFP-positive cells in BAC36 wt, RTA1st and RTAall recombinant viruses infected PBMCs. (A, B) KSHV BAC36 wt, RTA1st and RTAall viruses infected PBMCs were harvested at 1dpi, 2dpi, 4dpi and 7dpi. T cells and B cells were detected by using the APC-conjugated anti-CD3 and PerCP-Cy 5.5-conjugated anti-CD19 mAbs. GFP signals were monitored KSHV positive cells. Data were acquired on FACSCalibur equipped with CellQuest Pro software and analyzed using FlowJo software. (C) KSHV infected T cells (CD3+ GFP+). (D) KSHV infected B cells (CD19+ GFP+). (E) Total KSHV infected PBMC cells (GFP+). *P<0.05; **P<0.01; ***P<0.001 by Student’s t test (N = 9).

doi:10.1371/journal.ppat.1002479.g008
short [36]. This pattern was similar to transformed 293 cells in that RTA1st and RTAall recombinant viruses still enhanced population of T cells in PBMCs, suggesting that infected T cells may be latently infected. Our data also showed that the percentage of CD19 + GFP+ B cells was increased from 1dpi to 7dpi. Unexpectedly, B cell infection boosted the proliferation of infected cells in a time-dependent manner, though T cells are likely to suppress lytic replication of infected B cells. It may be the case that B cells are undergoing lytic cycle replication, releasing progeny which reinfect both T cells and B cells as there was a general increase in lytic cycle gene expression within 2dpi. The population of infected B cells began to decrease at 7dpi, though the number of infected T cells had peaked. As HIV infection may reduce the CD4+ T cell counts, KSHV infected T cells may maintain a fine balance in overall T cell population as well as promote cell proliferation and immortalization for B cells. Another possibility is that certain subpopulations of cells were significantly overactive and may restrict B cell proliferation. Recently, Myounge and Garmon showed that T cells from infected primary tonsillar lymphoid cells by KSHV did not support proper viral transcription and did not produce infectious virus. However, activated T cells may promote or stabilize latency of KSHV infected B cells [35,36]. Interestingly, we did not see proliferation of B cells but the percentage of infected B cells was decreased at 7dpi. Therefore we think other restrictive signals are involved in controlling latency of infected B cells, and so transformation for B cells was suppressed. After 7days post-infection, most cells died and no immortalization was observed. One reasonable explanation is that B cells can provide same paracrine signal activities to T cells but infected T cells may lack the ability to receive these signals from B cells, thus losing their proliferative capability. However, B cells may have a central role in infection and proliferation of PBMCs. After 7dpi, the efficiency of infection of B cells was decreased which led to a dramatic reduction in proliferation of the KSHV infected PBMCs. Did the presence of more T cells which were continuously infected destroy the population balance of PBMCs? Do B cells drive essential signaling important for T cells proliferation? These questions merit further investigation. In addition, GFP positive signals showed that more cells were infected in a time-dependent manner. We ruled out the possibility that TPA may have caused this effect in infected T and B cells, as a side-by-side comparison between BAC36 wt, RTA1st and RTAall recombinant viruses strongly supported our conclusion [70]. We clearly showed that RTA1st and RTAall viruses infected total GFP-positive B and T cells showed a prominent increase relative to BAC36 wt in PBMCs up to 7dpi. These results further support our hypothesis that mutation of RBP-Jκ in the RTA promoter can enhance KSHV latent infection of both of B and T cells in PBMCs during primary infection.

The expression of total mRNA from infected PBMCs provides additional information and further reinforces the pattern of KSHV infection. RTA1st and RTAall recombinant viruses showed a decrease in K8 expression, though the down-regulation was not necessarily as strong as in B cells infected with RTA-deficient virus [23]. However, this is reasonable because neither RTA1st nor RTAall recombinant viruses abrogated viral lytic capabilities. RTA1st and RTAall recombinant viruses up-regulated KSHV ORF6 (SSB, single-stranded DNA binding protein) indicating that viral DNA replication is active in infected PBMCs. LANA expression was also up-regulated, suggesting a more tightly latent infection due to the action of LANA on RBP-Jκ. ORF 49 expression was down-regulated in RTA1st and RTAall recombinant viruses infected PBMCs, suggesting that these recombinant viruses may in part lose their lytic capability. Interestingly, the mRNA levels of ORF K8 which is a direct target of RTA [71], was significantly decreased in RTA1st and RTAall recombinant viruses infected PBMCs, strongly suggesting that the two recombinant viruses possess a reduced capability for lytic replication during primary infection. Overall, these data further supports our hypothesis that recombinant RTA1st and RTAall viruses are enhanced in their ability to maintain latency after infection of primary cells.

Though PBMCs were effectively infected, long-term infection of B and T cells was not supported. RTA1st and RTAall recombinant viruses showed on increase in genome copies in long-term-infected TIVE cells providing evidence that mutation of the RBP-Jκ sites within the RTA promoter enhanced KSHV latent infection and induces the proliferative capability of the infected primary cells.

In conclusion, we have now experimentally shown that KSHV recombinant viruses with mutated RBP-Jκ sites within the RTA promoter possess an enhanced ability to maintain latent infection in transformed-293 cells as well as PBMCs during early infection. Our studies further confirm and define our previously published data which showed the effects on truncation of the RTA promoter and has important implications regarding the development of KSHV-associated lymphoproliferative disease. These recombinant viruses now provide a model which can be used to explore the early stages of primary infection in human PBMCs as well as the development of KSHV-associated lymphoproliferative diseases.

Acknowledgments

We thank Dr. Shou-Jiang Gao (University of Texas) for the BAC36 KSHV-GFP BACmid and Dr. Rolf Renne (University of Florida) and Michael Lagunoff (University of Washington) for the telomerase-immortalized human umbilical vein endothelial (TIVE) cells. We also thank Dr. Sabyasachi Haldar for assistance in generation of RTAall recombinant virus.

Author Contributions

Conceived and designed the experiments: JL SCV ESR. Performed the experiments: JL QC RKD. Analyzed the data: JL SCV. Contributed reagents/materials/analysis tools: AS. Wrote the paper: JL ESR.

References

1. Cesarmian E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186–1191.

2. Soulier J, Grollet L, Oktenhendler E, Gacoub P, Cazals-Hatem D, et al. (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86: 1276–1280.

3. Ganem D (1992) Kaposi’s sarcoma-associated herpesvirus latency and disease progression. Annu Rev Microbiol 46: 569–590.
27. Liang Y, Ganem D (2004) RBP-J (CSL) is essential for activation of the K14/keratin promoter by the KSHV lytic transactivator RTA. J Virol 79: 151–165.

28. Lan K, Kuppers DA, Verma SC, Sharma N, Murakami M, et al. (2005) Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol 79: 7453–7465.

29. Chang PJ, Boonstorp J, Wang SS, Chen LY, Miller G (2010) Binding of RBP-Jkappa (CSL) protein to the promoter of the Kaposi's sarcoma-associated herpesvirus ORF50 (kappaB) is a critical but not sufficient determinant of transcription by ORF50 protein. Virology 398: 38–48.

30. Lan K, Kuppers DA, Robertson ES (2005) Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol 79: 3468–3478.

31. Mesri EA, Cesarman E, Boshoff C (2010) Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10: 707–719.

32. Aller C, Birkenbach M, Kieff E (1991) Early Events in Epstein-Barr virus infection of human B lymphocytes. Virology 181: 595–608.

33. Ballon G, Chen K, Perez R, Tam W, Cesarman E (2011) Kaposi sarcoma herpesvirus (KSHV) VFLIP oncoprotein induces B cell transdifferentiation and lymphomagenesis in mice. J Clin Invest 121: 1141–1153.

34. Hassman LM, Ellison TJ, Kedes DH (2011) KSHV infection of a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 121: 752–768.

35. Myoung J, Ganem D (2011) Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. J Clin Invest 121: 1130–1140.

36. Myoung J, Ganem D (2011) Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. Virology 415: 1–11.

37. Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, et al. (1996) Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 10: 175–180.

38. Camara Pierotti L, Masami Sumita L, Santos Freire W, Helo Caiapia Filho H, de Souza VA (2008) Detection of human herpesvirus 8 DNA and antibodies to latent nuclear and lytic-phase antigens in serial samples from aids patients with Kaposi's sarcoma. J Clin Virol 41: 247–251.

39. Cattani L, Passano M, Parodi A, de Girolamo G, Guido R, Santangelo R, et al. (1998) Human herpes virus 8 in Italian HIV-seropositive patients with Kaposi's sarcoma. Arch Dermatol 134: 693–699.

40. Zhu B, Chen Y, Xie Y, Wu N, Shendu J, et al. (2008) Kaposi's sarcoma-associated herpesvirus K8 protein interacts with CREB-binding protein (CBP) and represses CBP-mediated transcription. J Virol 75: 9509–9516.

41. Polakova MM, Goudjim M, Cornelissen M (2001) Identification and characterization of the Orf49 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 75: 2750–2755.

42. Chang H, Wachmann LM, Pearson CB, Lee J, Lee HR, et al. (2009) Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog 5: e1000606.

43. Lu J, Verma SC, Cai Q, Robertson ES (2011) The single RBP-Jkappa (Ckappa) site within the LANA promoter is crucial for establishing KSHV latency during primary infection. J Virol 85: 6148–6161.

44. An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, et al. (2008) Long-term infected telomerase-immortalized endothelial cells a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 82: 4833–4846.

45. Xie Y, Rodríguez-Huete A, Pari GS (2006) Evaluation of the lytic origins of replication of Kaposi's sarcoma-associated herpesvirus in the context of the viral genome. J Virol 80: 9905–9909.

46. Cai Q, Verma SC, Choi JY, Ma M, Robertson ES (2010) Kaposi's sarcoma-associated herpesvirus inhibits interleukin-6-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency. J Virol 84: 4367–4376.

47. Halder S, Murakami M, Verma SC, Kumar P, Y F, et al. (2009) Early Events associated with infection of Epstein-Barr virus infection of primary B cells. PLoS One 4: e7214.

48. Zhou FC, Zhang YJ, Deng JH, Wang XP, Pan HY, et al. (2002) Efficient transduction of polyadenylated nuclear RNA by RTA in human herpesvirus 8/Kaposi's sarcoma-associated herpesvirus reactivation is regulated by interaction of latency-associated nuclear antigen with recombination signal sequence-binding protein Jkappa, the major downstream effector of the Notch signaling pathway. J Virol 79: 3468–3478.

49. Alfreider C, Birkenbach M, Kieff E (1991) Early Events in Epstein-Barr virus infection of human B lymphocytes. Virology 181: 595–608.

50. Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, et al. (1996) Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 10: 175–180.

51. Polakova MM, Goudjim M, Cornelissen M (2001) Identification and characterization of the Orf49 protein of Kaposi's sarcoma-associated herpesvirus. J Virol 75: 2750–2755.

52. Chang H, Wachmann LM, Pearson CB, Lee J, Lee HR, et al. (2009) Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog 5: e1000606.

53. Lu J, Verma SC, Cai Q, Robertson ES (2011) The single RBP-Jkappa (Ckappa) site within the LANA promoter is crucial for establishing KSHV latency during primary infection. J Virol 85: 6148–6161.

54. An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, et al. (2008) Long-term infected telomerase-immortalized endothelial cells a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 82: 4833–4846.

55. Xie Y, Rodríguez-Huete A, Pari GS (2006) Evaluation of the lytic origins of replication of Kaposi's sarcoma-associated herpesvirus in the context of the viral genome. J Virol 80: 9905–9909.
herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J Virol 77: 9590–9612.

57. Izumiya Y, Lin SF, Ellison T, Chen LY, Izumiya C, et al. (2003) Kaposi’s sarcoma-associated herpesvirus K-bZIP is a coregulator of K-Rta: physical association and promoter-dependent transcriptional repression. J Virol 77: 1441–1451.

58. Liao W, Tang Y, Lin SF, Kang Hj, Giam CZ (2003) K-bZIP of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) binds KSHV/HHV-8 Rta and represses Rta-mediated transactivation. J Virol 77: 3809–3815.

59. Damania B (2007) DNA tumor viruses and human cancer. Trends Microbiol 15: 38–44.

60. Roperto S, Brun R, Paolini F, Urraro C, Russo V, et al. (2008) Detection of bovine papillomavirus type 2 in the peripheral blood of cattle with urinary bladder tumours: possible biological role. J Gen Virol 89: 3027–3033.

61. Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, et al. (2005) Could human papillomaviruses be spread through blood? J Clin Microbiol 43: 5428–5434.

62. Roperto S, Comazzi S, Cianani E, Paolini F, Borraccio G, et al. (2011) Peripheral blood mononuclear cells are additional sites of productive infection of bovine papillomavirus type 2. J Gen Virol 92: 1787–1794.

63. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture–produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48: 1043–1050.

64. Drummond JE, Shah KV, Saral R, Santos GW, Donnenberg AD (1987) BK virus specific humoral and cell mediated immunity in allogeneic bone marrow transplant (BMT) recipients. J Med Virol 23: 331–344.

65. Drummond JE, Shah KV, Donnenberg AD (1985) Cell-mediated immune responses to BK virus in normal individuals. J Med Virol 17: 237–247.

66. Dorries K, Shiera S, Dreses K, Arendt G, Eggers C, et al. (2003) Association of human polyomavirus JC with peripheral blood of immunocompromised and healthy individuals. J Neurovirol 9 Suppl 1: 81–87.

67. Siriani MC, Vincenzi L, Topino S, Scala E, Angeloni A, et al. (1997) Human herpesvirus 8 DNA sequences in CD8+ T cells. J Infect Dis 176: 541.

68. Harrington WJ, Jr., Bagarca O, Sosa CE, Bobroski LE, Baum M, et al. (1996) Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi’s sarcoma patients. J Infect Dis 174: 1101–1105.

69. Boshoff C, Whitby D, Hatzioannou T, Fischer C, van der Walt J, et al. (1995) Kaposi’s-sarcoma-associated herpesvirus in HIV-negative Kaposi’s sarcoma. Lancet 345: 1043–1044.

70. Myoung J, Ganem D (2011) Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: Maintenance of tight latency with efficient reactivation upon induction. J Virol Methods 174: 12–21.

71. Bu W, Palmeri D, Krishnan R, Marin R, Aris VM, et al. (2008) Identification of direct transcriptional targets of the Kaposi’s sarcoma-associated herpesvirus Rta lytic switch protein by conditional nuclear localization. J Virol 82: 10679–10723.